Alfaxalone

DB11371

small molecule vet_approved

Deskripsi

Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. It is used in veterinary practice under the trade name Alfaxan, and is licensed for use in both dogs and cats. Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.

Struktur Molekul 2D

Berat 332.484
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

667 Data
Buprenorphine Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Hydrocodone Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Magnesium sulfate The therapeutic efficacy of Alfaxalone can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Alfaxalone may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Mirtazapine Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Orphenadrine Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Pramipexole Alfaxalone may increase the sedative activities of Pramipexole.
Ropinirole Alfaxalone may increase the sedative activities of Ropinirole.
Rotigotine Alfaxalone may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Alfaxalone.
Sodium oxybate Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Thalidomide Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Alfaxalone.
Ethanol Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Fluvoxamine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Alfaxalone is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Alfaxalone is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Alfaxalone is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Alfaxalone is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Alfaxalone is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Alfaxalone is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Alfaxalone is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Alfaxalone.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Alfaxalone.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Alfaxalone.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Alfaxalone.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Alfaxalone.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Alfaxalone.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Alfaxalone.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Alfaxalone.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Alfaxalone.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Alfaxalone.
Dosulepin The risk or severity of CNS depression can be increased when Dosulepin is combined with Alfaxalone.
Zopiclone The risk or severity of adverse effects can be increased when Alfaxalone is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Alfaxalone.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Alfaxalone.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Alfaxalone.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Alfaxalone.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Alfaxalone.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Alfaxalone.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Alfaxalone.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Alfaxalone.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Alfaxalone.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Alfaxalone.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Alfaxalone.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Alfaxalone.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Alfaxalone.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Alfaxalone.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Alfaxalone.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Alfaxalone.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Alfaxalone.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Alfaxalone.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Alfaxalone.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Alfaxalone.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Alfaxalone.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Alfaxalone.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Alfaxalone.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Alfaxalone.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Alfaxalone.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Alfaxalone.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Alfaxalone.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Alfaxalone.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Alfaxalone.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Alfaxalone.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Alfaxalone.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Alfaxalone.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Alfaxalone.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Alfaxalone.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Alfaxalone.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Alfaxalone.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Alfaxalone.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Alfaxalone.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Alfaxalone.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Alfaxalone.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Alfaxalone.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Alfaxalone.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 19202182
    Roan R: Use of alfaxalone in rabbits. Vet Rec. 2009 Feb 7;164(6):188.
  • PMID: 18194193
    Strachan FA, Mansel JC, Clutton RE: A comparison of microbial growth in alfaxalone, propofol and thiopental. J Small Anim Pract. 2008 Apr;49(4):186-90. doi: 10.1111/j.1748-5827.2007.00473.x. Epub 2008 Jan 11.
  • PMID: 23611452
    Vettorato E: Prolonged intravenous infusion of alfaxalone in a cat. Vet Anaesth Analg. 2013 Sep;40(5):551-2. doi: 10.1111/vaa.12044. Epub 2013 Apr 24.
  • PMID: 23385007
    Herbert GL, Murison PJ: Eye position of cats anaesthetised with alfaxalone or propofol. Vet Rec. 2013 Apr 6;172(14):365. doi: 10.1136/vr.101404. Epub 2013 Feb 5.
  • PMID: 22642499
    Goodwin W, Keates H, Pasloske K, Pearson M, Sauer B, Ranasinghe MG: Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. Vet Anaesth Analg. 2012 Sep;39(5):503-10. doi: 10.1111/j.1467-2995.2012.00734.x. Epub 2012 May 30.
  • PMID: 21831051
    Bertelsen MF, Sauer CD: Alfaxalone anaesthesia in the green iguana (Iguana iguana). Vet Anaesth Analg. 2011 Sep;38(5):461-6. doi: 10.1111/j.1467-2995.2011.00640.x.
  • PMID: 6846760
    Jungck E, Kloss T, Blendl M, Hoerster W, Klaucke D: Experiences with the steroid narcotic alfaxalone/alfadolone (Aurantex) in emergency patients in rescue service. Anasth Intensivther Notfallmed. 1983 Feb;18(1):8-13.
  • PMID: 2600731
    Brewster ME, Estes KS, Bodor N: Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins. J Parenter Sci Technol. 1989 Nov-Dec;43(6):262-5.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul